Headlines about Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been trending positive this week, according to Alpha One Sentiment. The research firm, a unit of Accern, scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Integra LifeSciences Holdings Corporation earned a news sentiment score of 0.29 on Alpha One’s scale. Alpha One also gave media headlines about the life sciences company an impact score of 69 out of 100, meaning that recent media coverage is likely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected AlphaOne’s analysis:
- Integra LifeSciences to Hold Second International Tissue Technologies Symposium on June 15 – 16, 2017 in Berlin, Germany (feeds.benzinga.com)
- Were Analysts Bullish Integra Lifesciences Holdings Corp (NASDAQ:IART) This Week? (healthcaremenu.net)
- Western Alliance Bancorporation (WAL) Shares Sold by Strategic Global Advisors LLC (campdesrecrues.com)
- New Study: Integra LifeSciences Holdings Corp (IART) – Product Pipeline Analysis, 2017 Update (reports.pr-inside.com)
- Endologix (ELGX) & Integra Lifesciences Holdings Corp (IART) Financial Analysis (americanbankingnews.com)
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.13% on Friday, hitting $52.79. 924,301 shares of the stock traded hands. The stock has a market cap of $3.99 billion, a price-to-earnings ratio of 62.85 and a beta of 0.76. The stock has a 50-day moving average price of $48.87 and a 200 day moving average price of $51.04. Integra LifeSciences Holdings Corporation has a 12-month low of $37.38 and a 12-month high of $53.07.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.39 EPS for the quarter, missing the consensus estimate of $0.40 by $0.01. Integra LifeSciences Holdings Corporation had a net margin of 6.66% and a return on equity of 16.67%. The company had revenue of $258.60 million for the quarter, compared to analyst estimates of $254.19 million. During the same quarter last year, the business earned $0.38 EPS. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.92 earnings per share for the current fiscal year.
IART has been the subject of several research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $47.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, March 22nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, March 22nd. Jefferies Group LLC boosted their price objective on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Royal Bank of Canada reiterated a “sector perform” rating and set a $48.00 price objective (up from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, May 2nd. Finally, ValuEngine downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $49.50.
In other news, VP Glenn Coleman sold 13,865 shares of the firm’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $45.91, for a total value of $636,542.15. Following the sale, the vice president now owns 18,519 shares in the company, valued at $850,207.29. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James M. Sullivan sold 15,658 shares of the firm’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $45.89, for a total transaction of $718,545.62. Following the completion of the sale, the director now owns 70,154 shares in the company, valued at approximately $3,219,367.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 304,523 shares of company stock worth $14,812,988. 21.40% of the stock is currently owned by corporate insiders.
Integra LifeSciences Holdings Corporation Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229376/integra-lifesciences-holdings-corporation-iart-earning-positive-news-coverage-study-finds.html
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.